The panel tested for the presence cfDNA KRAS mutations and serum levels of CA19-9, CEA, HGF and OPN—protein markers that are used clinically to follow pancreatic cancer patient treatment course or have been previously found to be dysregulated in pancreatic cancer patients. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.